ATE299022T1 - Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis - Google Patents

Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis

Info

Publication number
ATE299022T1
ATE299022T1 AT02736467T AT02736467T ATE299022T1 AT E299022 T1 ATE299022 T1 AT E299022T1 AT 02736467 T AT02736467 T AT 02736467T AT 02736467 T AT02736467 T AT 02736467T AT E299022 T1 ATE299022 T1 AT E299022T1
Authority
AT
Austria
Prior art keywords
cyclopamine
treatment
psoriasis
production
medicinal product
Prior art date
Application number
AT02736467T
Other languages
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE299022(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas filed Critical Sinan Tas
Application granted granted Critical
Publication of ATE299022T1 publication Critical patent/ATE299022T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02736467T 2001-07-02 2002-04-19 Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis ATE299022T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
PCT/TR2002/000017 WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis

Publications (1)

Publication Number Publication Date
ATE299022T1 true ATE299022T1 (de) 2005-07-15

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01952097T ATE305300T1 (de) 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
AT02736467T ATE299022T1 (de) 2001-07-02 2002-04-19 Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01952097T ATE305300T1 (de) 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren

Country Status (14)

Country Link
EP (4) EP1561464A3 (de)
JP (3) JP2004536045A (de)
KR (1) KR20090125833A (de)
CN (2) CN1525859B (de)
AT (2) ATE305300T1 (de)
AU (1) AU2001272892B8 (de)
BR (1) BR0117063A (de)
CA (1) CA2452151C (de)
DE (2) DE60113733T2 (de)
DK (2) DK1401438T3 (de)
ES (3) ES2250434T3 (de)
PT (1) PT1411938E (de)
RU (1) RU2312661C2 (de)
WO (2) WO2002078703A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
EP1411938B1 (de) 2001-07-02 2005-07-06 Tas, Sinan Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
EP1561464A3 (de) * 2001-07-02 2007-04-25 Sinan Tas Verwendung des Cyclopamins zur Behandlung des basalen Zellkarzinoms und anderer Tumoren
CA2619889C (en) * 2005-08-22 2020-05-05 The Johns Hopkins University Use of itraconazole and salts thereof for treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
AU2007329678A1 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
RU2009137012A (ru) 2007-03-07 2011-04-20 Инфинити Дискавери, Инк. (Us) Аналоги циклопаминлактама и способы их применения
JP2010520295A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド へテロ環状シクロパミン類似体及びその使用方法
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
US20240384291A1 (en) 2021-09-13 2024-11-21 Sinan Tas Effective Interventions With Aging and Diseases Of Aging Of Human and Their Consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
DK1115398T3 (da) * 1998-09-23 2010-08-16 Res Dev Foundation Tocopheroler, tocotrienoler, andre chroman- og sidekædederivater og anvendelser deraf
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1235851B1 (de) * 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
EP1646395B8 (de) * 1999-11-30 2014-12-17 Curis, Inc. Verfahren und zusammensetzungen zur regulierung der lymphozytenaktivität
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1561464A3 (de) * 2001-07-02 2007-04-25 Sinan Tas Verwendung des Cyclopamins zur Behandlung des basalen Zellkarzinoms und anderer Tumoren
EP1411938B1 (de) * 2001-07-02 2005-07-06 Tas, Sinan Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis

Also Published As

Publication number Publication date
BR0117063A (pt) 2004-07-27
DE60204966D1 (de) 2005-08-11
DK1411938T3 (da) 2005-11-07
CA2452151C (en) 2012-01-03
EP2216022A1 (de) 2010-08-11
AU2001272892B2 (en) 2006-03-16
ES2534400T3 (es) 2015-04-22
JP5424923B2 (ja) 2014-02-26
ATE305300T1 (de) 2005-10-15
WO2002078704A1 (en) 2002-10-10
RU2004103074A (ru) 2005-05-10
RU2312661C2 (ru) 2007-12-20
KR20090125833A (ko) 2009-12-07
JP2004536045A (ja) 2004-12-02
CA2452151A1 (en) 2002-10-10
DE60204966T2 (de) 2006-05-18
EP2216022B1 (de) 2015-01-07
JP2010132691A (ja) 2010-06-17
DE60113733D1 (de) 2006-02-09
CN1230169C (zh) 2005-12-07
EP1561464A2 (de) 2005-08-10
CN1525859B (zh) 2010-05-05
CN1525859A (zh) 2004-09-01
DE60113733T2 (de) 2006-06-29
EP1401438A1 (de) 2004-03-31
EP2862570A1 (de) 2015-04-22
CN1522146A (zh) 2004-08-18
JP2014028834A (ja) 2014-02-13
EP1561464A3 (de) 2007-04-25
WO2002078703A8 (en) 2003-06-12
EP1401438B1 (de) 2005-09-28
PT1411938E (pt) 2005-11-30
WO2002078703A1 (en) 2002-10-10
DK1401438T3 (da) 2006-02-13
ES2246011T3 (es) 2006-02-01
ES2250434T3 (es) 2006-04-16
AU2001272892B8 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE267594T1 (de) Verwendung von albuminstabilisiertem paclitaxel zur herstellung eines arzneimittels zum behandeln von festen tumoren und das so erhaltene arzneimittel
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
DE59907752D1 (de) Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60135647D1 (de) Zusammensetzungen zur normalisierung des zirkadianen rythmus
EP1767212A4 (de) Verwendung der pflanze der gattung ampelopsis und deren extrakte zur herstellung von arzneimitteln und functional food
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
BR0213479A (pt) Utilização do irbesartan para a preparação de medicamentos úteis para a prevenção ou o tratamento da hipertensão pulmonar
DE60107900D1 (de) Pharmazeutische Zusammensetzung und Nahrungsmittel zur Behandlung von Gehirnödem
DE60216292D1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
DE60106890D1 (de) Verwendung von cdp-choline zur behandlung des alkoholentzugsyndroms
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
DE60128130D1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
DE60112253D1 (de) Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411938

Country of ref document: EP

REN Ceased due to non-payment of the annual fee